Pay in 4 interest-free payments of $7.07 Learn more
Ships within 48 hours · Estimated delivery Nov 17 - Nov 22
Data availability The full set of de-identified summary statistics can be made available to qualified investigators who enter into an agreement with 23andMe that protects participant confidentiality
United States Patent and Trademark Office
Side effects peak during weeks 6-8 and typically resolve by week 12, with 88.8% of participants completing the full 48-week trial successfully
Retatrutide (LY3437943) is an unlicensed investigational triple GIP, GLP-1, and glucagon receptor agonist with no MHRA or EMA marketing authorisation
US$ 29.27
US$ 20.15
US$ 28.45
US$ 25.26
